Atea Pharmaceuticals Stock Buy Hold or Sell Recommendation
| AVIR Stock | USD 3.37 0.12 3.69% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding Atea Pharmaceuticals is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Atea Pharmaceuticals given historical horizon and risk tolerance towards Atea Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Atea Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Atea Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Atea and provide practical buy, sell, or hold advice based on investors' constraints. Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Atea |
Execute Atea Pharmaceuticals Buy or Sell Advice
The Atea recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Atea Pharmaceuticals. Macroaxis does not own or have any residual interests in Atea Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Atea Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Atea Pharmaceuticals Trading Alerts and Improvement Suggestions
| Atea Pharmaceuticals generated a negative expected return over the last 90 days | |
| Net Loss for the year was (135.96 M) with loss before overhead, payroll, taxes, and interest of (81.94 M). | |
| Atea Pharmaceuticals currently holds about 684.48 M in cash with (85.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Atea Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Is Atea Pharmaceuticals Stock Outpacing Its Medical Peers This Year |
Atea Pharmaceuticals Returns Distribution Density
The distribution of Atea Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Atea Pharmaceuticals' future price movements. The chart of the probability distribution of Atea Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Atea Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Atea Pharmaceuticals returns is essential to provide solid investment advice for Atea Pharmaceuticals.
| Mean Return | -0.14 | Value At Risk | -4.26 | Potential Upside | 4.19 | Standard Deviation | 2.69 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Atea Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Atea Stock Institutional Investors
The Atea Pharmaceuticals' institutional investors refer to entities that pool money to purchase Atea Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 793.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 735.1 K | Northern Trust Corp | 2024-09-30 | 687.4 K | Charles Schwab Investment Management Inc | 2024-09-30 | 650.2 K | Two Sigma Advisers, Llc | 2024-06-30 | 612.2 K | Federated Hermes Inc | 2024-09-30 | 572.1 K | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 564.9 K | Citadel Advisors Llc | 2024-06-30 | 525.6 K | Newtyn Management Llc | 2024-06-30 | 380 K | Blackrock Inc | 2024-06-30 | 9.1 M | Bml Capital Management Llc | 2024-09-30 | 6.7 M |
Atea Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (2K) | (26K) | (4K) | (455.4M) | 40.3M | 42.3M | |
| Change In Cash | (12.8M) | 828.5M | (85.5M) | (576.0M) | (44.8M) | (42.6M) | |
| Free Cash Flow | (12.8M) | 296.7M | (87.0M) | (122.9M) | (85.4M) | (81.1M) | |
| Other Non Cash Items | 501K | 13.8M | 29.4M | (5.5M) | 33.1M | 34.8M | |
| Net Income | (14.0M) | (10.9M) | 121.2M | (115.9M) | (136.0M) | (129.2M) | |
| End Period Cash Flow | 21.8M | 850.2M | 764.7M | 188.7M | 143.8M | 136.6M | |
| Change To Netincome | 624K | 7.5M | 39.6M | 41.3M | 47.4M | 49.8M |
Atea Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Atea Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Atea Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Atea stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.39 | |
β | Beta against Dow Jones | 1.97 | |
σ | Overall volatility | 2.66 | |
Ir | Information ratio | -0.1 |
Atea Pharmaceuticals Volatility Alert
Atea Pharmaceuticals exhibits very low volatility with skewness of 0.13 and kurtosis of 0.29. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Atea Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Atea Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Atea Pharmaceuticals Fundamentals Vs Peers
Comparing Atea Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Atea Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Atea Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Atea Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Atea Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Atea Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Atea Pharmaceuticals to competition |
| Fundamentals | Atea Pharmaceuticals | Peer Average |
| Return On Equity | -0.33 | -0.31 |
| Return On Asset | -0.14 | -0.14 |
| Current Valuation | (196.34 M) | 16.62 B |
| Shares Outstanding | 84.46 M | 571.82 M |
| Shares Owned By Insiders | 9.67 % | 10.09 % |
| Shares Owned By Institutions | 71.00 % | 39.21 % |
| Number Of Shares Shorted | 2.59 M | 4.71 M |
| Price To Earning | 15.03 X | 28.72 X |
| Price To Book | 0.62 X | 9.51 X |
| Price To Sales | 1.90 X | 11.42 X |
| Gross Profit | (81.94 M) | 27.38 B |
| EBITDA | (119.59 M) | 3.9 B |
| Net Income | (135.96 M) | 570.98 M |
| Cash And Equivalents | 684.48 M | 2.7 B |
| Cash Per Share | 8.22 X | 5.01 X |
| Total Debt | 2.4 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 27.46 X | 2.16 X |
| Book Value Per Share | 5.43 X | 1.93 K |
| Cash Flow From Operations | (85.39 M) | 971.22 M |
| Short Ratio | 18.59 X | 4.00 X |
| Earnings Per Share | (2.07) X | 3.12 X |
| Target Price | 6.89 | |
| Number Of Employees | 75 | 18.84 K |
| Beta | 0.17 | -0.15 |
| Market Capitalization | 284.64 M | 19.03 B |
| Total Asset | 594.97 M | 29.47 B |
| Retained Earnings | (195.84 M) | 9.33 B |
| Working Capital | 558.08 M | 1.48 B |
| Current Asset | 97.88 M | 9.34 B |
| Current Liabilities | 6.25 M | 7.9 B |
| Net Asset | 594.97 M |
Note: Disposition of 17544 shares by Polsky Bruce of Atea Pharmaceuticals at 3.4852 subject to Rule 16b-3 [view details]
Atea Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Atea . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Atea Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Atea Pharmaceuticals? Buying financial instruments such as Atea Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Atea Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.